1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [2f8aff6e-458f-4895-9222-4c4365651a38] => Array
        (
            [runtime-id] => 2f8aff6e-458f-4895-9222-4c4365651a38
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [45d19413-4cb0-4620-aaae-4565ffcae7ac] => Array
                        (
                            [runtime-id] => 45d19413-4cb0-4620-aaae-4565ffcae7ac
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [0aaf7f5e-e1a1-4ca5-862d-9d892a05cb08] => Array
        (
            [runtime-id] => 0aaf7f5e-e1a1-4ca5-862d-9d892a05cb08
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [7e953597-288c-47d5-b32a-4fd63edb31bf] => Array
                        (
                            [runtime-id] => 7e953597-288c-47d5-b32a-4fd63edb31bf
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [ca027d8b-afcf-4356-8832-5f8c388cb73d] => Array
        (
            [runtime-id] => ca027d8b-afcf-4356-8832-5f8c388cb73d
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [783d3067-7a12-4d32-a519-59cf5f2e10eb] => Array
                        (
                            [runtime-id] => 783d3067-7a12-4d32-a519-59cf5f2e10eb
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [76d2a4e8-b2ee-47e3-b670-414031cc898a] => Array
        (
            [runtime-id] => 76d2a4e8-b2ee-47e3-b670-414031cc898a
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [2ce9f9f5-d5f2-4105-a57a-18174ad50bb1] => Array
                        (
                            [runtime-id] => 2ce9f9f5-d5f2-4105-a57a-18174ad50bb1
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [76d2a4e8-b2ee-47e3-b670-414031cc898a] => Array
        (
            [runtime-id] => 76d2a4e8-b2ee-47e3-b670-414031cc898a
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [2ce9f9f5-d5f2-4105-a57a-18174ad50bb1] => Array
                        (
                            [runtime-id] => 2ce9f9f5-d5f2-4105-a57a-18174ad50bb1
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [2f8aff6e-458f-4895-9222-4c4365651a38] => Array
        (
            [runtime-id] => 2f8aff6e-458f-4895-9222-4c4365651a38
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [45d19413-4cb0-4620-aaae-4565ffcae7ac] => Array
                        (
                            [runtime-id] => 45d19413-4cb0-4620-aaae-4565ffcae7ac
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [2f8aff6e-458f-4895-9222-4c4365651a38] => Array
        (
            [runtime-id] => 2f8aff6e-458f-4895-9222-4c4365651a38
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [45d19413-4cb0-4620-aaae-4565ffcae7ac] => Array
                        (
                            [runtime-id] => 45d19413-4cb0-4620-aaae-4565ffcae7ac
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [2f8aff6e-458f-4895-9222-4c4365651a38] => Array
        (
            [runtime-id] => 2f8aff6e-458f-4895-9222-4c4365651a38
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [45d19413-4cb0-4620-aaae-4565ffcae7ac] => Array
                        (
                            [runtime-id] => 45d19413-4cb0-4620-aaae-4565ffcae7ac
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [2f8aff6e-458f-4895-9222-4c4365651a38] => Array
        (
            [runtime-id] => 2f8aff6e-458f-4895-9222-4c4365651a38
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [45d19413-4cb0-4620-aaae-4565ffcae7ac] => Array
                        (
                            [runtime-id] => 45d19413-4cb0-4620-aaae-4565ffcae7ac
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [9d39cb05-3ec5-439b-aaeb-18f9b0772dfc] => Array
        (
            [runtime-id] => 9d39cb05-3ec5-439b-aaeb-18f9b0772dfc
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [cccbd39c-d03c-4474-975b-d9230d0d6561] => Array
                        (
                            [runtime-id] => cccbd39c-d03c-4474-975b-d9230d0d6561
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;f34606b3d42d437c2d0b242593f71ddeb8a40572
                )

        )

)


  
    


































































    Panitumumab (Vectibix) | American Journal of Neuroradiology  
    


















    

































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      



          


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticlePharmacology Vignette

  
      

  
      
Panitumumab (Vectibix)
  
    	
J.J. Gemmete and S.K. Mukherji

  
    	
American Journal of Neuroradiology June 2011,  32 (6) 1002-1003; DOI: https://doi.org/10.3174/ajnr.A2601 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


SUMMARY:


Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody.


Abbreviations
c-erbB-1
EGFR gene
EGFR
epidermal growth factor receptor
FDA
US Food and Drug Administration
HER
human epidermal growth factor receptor
KRAS
Kristen rat sarcoma viral oncogene homolog
Panitumumab is a human monoclonal antibody antagonist specific to the EGFR (also known as EGF receptor, c-erbB-1, and HER1 in humans).1 It is indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimen.2–4 Drug approval by the FDA is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with panitumumab.5 Panitumumab is manufactured by Amgen (Thousand Oaks, California) and is marketed as Vectibix.


Mechanism of Action


EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including HER2, HER3, and HER4.6 EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicles. EGFR is overexpressed in certain human cancers, including colon and rectal cancer. Panitumumab works by binding to the extracellular domain of the EGFR preventing its activation.7 This results in halting of the cascade of intracellular signals dependent on this receptor (Fig 1).


Fig 1.
Fig 1. 

Schematic illustration of the proposed mechanism of panitumumab. Panitumumab is a monoclonal antibody that binds to the extracellular portion of the EGFR preventing dimerization and the cascade that leads to the expression of growth factors. (Illustration courtesy of Carolyn Nowak.)




Clinical Indication


The FDA approved panitumumab for the first time in September 2006, for the treatment of EGFR-expressing metastatic colorectal cancer with disease progression despite prior treatment. Panitumumab was approved by the European Medicines Agency in 2007 and by Health Canada in 2008 for the treatment of refractory EGFR-expressing metastatic colorectal cancer with nonmutated (wild-type) KRAS. Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.8




Administration and Side Effects


Panitumumab is administered at 6 mg/kg every 14 days as an intravenous infusion for 60 minutes (≤1000 mg) or 90 minutes (>1000 mg). Panitumumab administered as a single agent exhibits nonlinear pharmacokinetics. The elimination half-life is approximately 7.5 days (range, 3.6–10.9 days). No formal pharmacokinetic studies of panitumumab have been conducted in patients with renal or hepatic impairment, to our knowledge.


The most common adverse reactions (≥20%) are skin toxicities (ie, erythema, dermatitis acneiform, pruritus, exfoliation, rash, and fissures), paronychia, hypomagnesemia, fatigue, abdominal pain, nausea, diarrhea, and constipation. The most serious adverse events with the administration of panitumumab include pulmonary fibrosis, pulmonary embolism, and severe dermatologic toxicity. Electrolyte levels should be monitored along with clinical signs of dermatologic and ocular toxicity.9,10




Economic Issues


Like other genetically engineered monoclonal antibodies, panitumumab is quite expensive, and the costs can vary widely from country to country. Panitumumab costs approximately $3000 per treatment in the United States based on an average healthy male weight of 70 kg.


Footnotes
  • 

    DISCLOSURES: Suresh K. Mukherji, Consultant: Philips Healthcare.
References
  1. 1.↵


    1. Cohen  RB
    .
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Clin Colorectal Cancer
2003;
2:
246–
51

    PubMed
    

  2. 2.↵


    1. Kim  GP, 
    2. Grothey  A
    .
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.
Biologics
2008;
2:
223–
28

    PubMed
    

  3. 3.↵


    1. Keating  GM
    .
Spotlight on panitumumab in metastatic colorectal cancer.
BioDrugs
2010;
1
24:
275–
78

    

  4. 4.↵


    1. Keating  GM
    .
Panitumumab: a review of its use in metastatic colorectal cancer.
Drugs 28
2010;
70:
1059–
78

    CrossRefPubMed
    

  5. 5.↵


    1. Hoda  D, 
    2. Simon  GR, 
    3. Garrett  CR
    .
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.
Ther Clin Risk Manag
2008;
4:
1221–
27

    PubMed
    

  6. 6.↵


    1. Martinelli  E, 
    2. De Palma  R, 
    3. Orditura  M, 
    4. et al
    .
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
Clin Exp Immunol
2009;
158:
1–
9

    PubMed
    

  7. 7.↵


    1. Dubois  EA, 
    2. Cohen  AF
    .
Panitumumab.
Br J Clin Pharmacol
2009;
68:
482–
83

    CrossRefPubMed
    

  8. 8.↵


    1. Berardi  R, 
    2. Onofri  A, 
    3. Pistelli  M, 
    4. et al
    .
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.
Core Evid
2010;
5:
61–
76

    PubMed
    

  9. 9.↵


    Vectibix (panitumumab) [package insert].
Thousand Oaks, California: Amgen Inc; 
2006
    

  10. 10.↵


    1. Gerber  DE
    .
Targeted therapies: a new generation of cancer treatments.
Am Fam Physician
2008;
77:
311–
19

    PubMed
    

View Abstract
  


  
  



  
      
  
  

    
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Panitumumab (Vectibix)
  
    	
J.J. Gemmete, S.K. Mukherji

  
    	
American Journal of Neuroradiology Jun 2011, 32 (6) 1002-1003; DOI: 10.3174/ajnr.A2601 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    

  

    
 Related Articles
  • No related articles found.
 Cited By...
 More in this TOC Section
 Similar Articles

  



  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement